Light therapy for dry macular degeneration in one eye
Part of Eyes & vision clinical trials.
This trial studies whether a light-based treatment (photobiomodulation) can help people with dry age-related macular degeneration in one eye. Because one eye is treated while the other eye has a different type of AMD in the study design, eligibility depends on which type of AMD you have in each eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have dry age-related macular degeneration (AMD) in the eye being treated
- You have wet AMD in the other (control) eye
- You do not have central “geographic atrophy” in the center of the retina at the start
- You have no history of epilepsy
- You don’t have other major retinal diseases besides AMD
- Your vision media are clear enough (no significant haze/blocking) and cataracts are not worse than grade 2
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special light treatment (photobiomodulation) can help people with dry age-related macular degeneration (AMD). It is designed for those with early to moderate dry AMD who still have fairly good vision.
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This Phase 1 trial tests the safety and side effects of ASP7317 in older adults whose central vision is worsening from dry age-related macular degeneration (geographic atrophy). If you qualify, you would receive treatment in the study eye and be closely monitored for about a year.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
This study tests a light-based treatment (photobiomodulation) for dry AMD, using the Valeda Light Delivery System. It may help improve vision and eye health over time.
Hear when a new Photobiomodulation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.